Tobacco Smoking or Nicotine Phenotype and Severity of Clinical Presentation at the Emergency Department (SMOPHED): Protocol for a Noninterventional Observational Study
- PMID: 38657239
- PMCID: PMC11079756
- DOI: 10.2196/54041
Tobacco Smoking or Nicotine Phenotype and Severity of Clinical Presentation at the Emergency Department (SMOPHED): Protocol for a Noninterventional Observational Study
Abstract
Background: In the last few years, several nicotine products have become available as alternatives to smoking tobacco. While laboratory and limited clinical studies suggest that these devices are less toxic compared to classic tobacco cigarettes, very little is known about their epidemiological impact. Visiting the emergency department (ED) often represents the first or even the only contact of patients with the health care system. Therefore, a study conducted at the ED to assess the impact of these products on health can be reliable and reflect a real-life setting.
Objective: The aim of this noninterventional observational study (SMOPHED study) is to analyze the association between the severity of clinical presentation observed during ED visits among patients using various nicotine products and the subsequent outcomes, specifically hospitalization and mortality.
Methods: Outcomes (hospitalization and mortality in the ED) will be examined in relation to various patterns of nicotine products use. We plan to enroll approximately 2000 participants during triage at the ED. These individuals will be characterized based on their patterns of tobacco and nicotine consumption, identified through a specific questionnaire. This categorization will allow for a detailed analysis of how different usage patterns of nicotine products correlate with the clinical diagnosis made during the ED visits and the consequent outcomes.
Results: Enrollment into the study started in March 2024. We enrolled a total of 901 participants in 1 month (approximately 300 potential participants did not provide the informed consent to participate). The data will be analyzed by a statistician as soon as the database is completed. Full data will be published by December 2024.
Conclusions: There is substantial debate about the harm reduction potential of alternative nicotine products in terms of their smoking-cessation and risk-reduction potential. This study represents an opportunity to document epidemiological data on the link between the use of different types of nicotine products and disease diagnosis and severity during an ED visit, and thus evaluate the harm reduction potential claims for these products.
International registered report identifier (irrid): PRR1-10.2196/54041.
Keywords: NEWS; National Early Warning Score; electronic cigarettes; emergency department; heated tobacco products; nicotine/tobacco use; smoking.
©Davide Campagna, Konstantinos Farsalinos, Giorgio Costantino, Giuseppe Carpinteri, Pasquale Caponnetto, Francesca Cucuzza, Riccardo Polosa, SMOPHED Study Group. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 24.04.2024.
Conflict of interest statement
Conflicts of Interest: RP has received the following EU and governmental competitive grants: U-BIOPRED, AIR-PROM, Integral Rheumatology & Immunology Specialists Network (IRIS), Ministero dell’Università e della Ricerca (MUR) Piano Nazionale Ripresa Resilienza (PNRR) 3277/2021, PNRR 341/2022, and PNRR 411/2021 funded by NextGenerationEU of the European Commission. RP has also received investigator-initiated grants from Foundation for a Smoke Free World, Pfizer, GlaxoSmithKline, CV Therapeutics, NeuroSearch A/S, Sandoz, Merk Sharp & Dohme, Boehringer Ingelheim, Novartis, Arbi Group Srl, Duska Therapeutics, and Forest Laboratories. He is founder of the Center for Tobacco Prevention and Treatment and of the Center of Excellence for the Acceleration of Harm Reduction at Catania University. He has been consulting for Pfizer, Boehringer Ingelheim, Duska Therapeutics, Forest Laboratories, CV Therapeutics, Sermo Inc, GRG Health, Clarivate Analytics, Guidepoint Expert Network, and GLG Group. He receives textbook royalties from Elsevier and Edra Publishing. He is also Chair of the European Technical Committee for Standardization on “Requirements and test methods for emissions of electronic cigarettes” (CEN/TC 437; WG4) and scientific advisor at RIDE2Med Foundation. The other authors declare no competing interests related to this research.
Similar articles
-
Effects of reduced-risk nicotine-delivery products on smoking prevalence and cigarette sales: an observational study.Public Health Res (Southampt). 2023 Sep;11(7):1-39. doi: 10.3310/RPDN7327. Public Health Res (Southampt). 2023. PMID: 37795840
-
Validating a Patient-Reported Outcome Measure to Improve Emergency Department Asthma Care: Protocol for an Observational Study.JMIR Res Protoc. 2025 May 29;14:e67195. doi: 10.2196/67195. JMIR Res Protoc. 2025. PMID: 40440691 Free PMC article.
-
Clinical study protocol on electronic cigarettes and nicotine pouches for smoking cessation in Pakistan: a randomized controlled trial.Trials. 2024 Jan 2;25(1):9. doi: 10.1186/s13063-023-07876-y. Trials. 2024. PMID: 38167206 Free PMC article.
-
Effectiveness and Safety Profile of Alternative Tobacco and Nicotine Products for Smoking Reduction and Cessation: A Systematic Review.J Multidiscip Healthc. 2021 Jul 23;14:1955-1975. doi: 10.2147/JMDH.S319727. eCollection 2021. J Multidiscip Healthc. 2021. PMID: 34326646 Free PMC article. Review.
-
Potential effects of using non-combustible tobacco and nicotine products during pregnancy: a systematic review.Harm Reduct J. 2020 Mar 2;17(1):16. doi: 10.1186/s12954-020-00359-2. Harm Reduct J. 2020. PMID: 32122384 Free PMC article.
References
-
- Fact Sheets: Tobacco. World Health Organization. 2023. Jul 31, [2023-02-10]. https://www.who.int/news-room/fact-sheets/detail/tobacco .
-
- Moore D, Aveyard P, Connock M, Wang D, Fry-Smith A, Barton P. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. BMJ. 2009 Apr 02;338:b1024. doi: 10.1136/bmj.b1024. https://europepmc.org/abstract/MED/19342408 338/apr02_3/b1024 - DOI - PMC - PubMed
-
- Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation. 2010 Jan 19;121(2):221–229. doi: 10.1161/CIRCULATIONAHA.109.869008. https://europepmc.org/abstract/MED/20048210 CIRCULATIONAHA.109.869008 - DOI - PMC - PubMed
-
- Casella G, Caponnetto P, Polosa R. Therapeutic advances in the treatment of nicotine addiction: present and future. Ther Adv Chronic Dis. 2010 May;1(3):95–106. doi: 10.1177/2040622310374896. https://journals.sagepub.com/doi/10.1177/2040622310374896?url_ver=Z39.88... 10.1177_2040622310374896 - DOI - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous